Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44+CD117+ ovarian cancer stem cells

Fig. 4

Metformin inhibits CSCs in tumor spheres and regulates their self-renewal. Isolated CD44+CD117+ cancer cells were cultured in sphere medium for 24 hours and then incubated with or without 0.1 mM metformin. Seven days of treatment with 0.1 mM metformin failed to inhibit tumor sphere formation. Tumor spheres were then dissociated with 0.05 % trypsin and cultured in ultralow plates with 0.1 mM metformin. Metformin at 0.1 mM inhibits CD44+CD117+ cells forming spheres with serial passaging (a, b). Metformin at 0.1 mM also reduced the CD44+CD117+ cell population with serial passaging (n = 3) (c). Metformin at 0.1 mM significantly reduced Survivin but not Bcl-2 expression level, and upregulated Bax expression level in CD44+CD117+ cells (d). Representative cell cycle histograms following flow cytometric analysis of propidium iodide (PI)-stained CD44+CD117+ cells show no change in the percentage of cells entering the S phase upon 0.1 nM metformin treatment (e). * Significant difference compared with control (P < 0.05)

Back to article page